Related Experiment Video

Updated: Aug 7, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis

P Kelleher1, A Goodsall, A Mulgirigama

  • 1Dept of Immunology, Imperial College, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. p.kelleher@imperial.ac.uk

The European Respiratory Journal
|June 15, 2006
PubMed

Insights

Reduced interferon-gamma production is linked to severe pulmonary aspergillosis. Supplementing with interferon-gamma improved patient outcomes, suggesting its therapeutic potential for this fungal lung infection.

Area of Science:

  • Immunology
  • Pulmonology
  • Mycology

Background:

  • Aspergillus species cause diverse human pulmonary diseases.
  • Semi-invasive pulmonary aspergillosis presents a significant clinical challenge.
  • Interferon-gamma plays a crucial role in immune responses against fungal infections.

Observation:

  • Two patients with semi-invasive aspergillosis showed reduced interferon-gamma (IFN-γ) secretion from peripheral blood mononuclear cells post-stimulation.
  • Disease progression occurred despite standard anti-fungal treatments.

Findings:

  • Impaired IFN-γ production is linked to chronic pulmonary aspergillosis.
  • In vitro studies revealed diminished cellular immune response in affected patients.

Implications:

  • Adjunctive therapy with IFN-γ may improve clinical outcomes in refractory cases.
  • Cytokine therapy warrants further investigation for severe pulmonary fungal infections.
  • Understanding immune dysregulation is crucial for developing targeted treatments.

More Related Videos

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...